David Denton
Pfizer · USA
Track record: No forecast checked yet (5 not due, 7 being checked).
12forecasts & commitments on the record
58%can be checked as stated
38average ambiguity (0-100)
0goalpost moves recorded
0confirmed U-turns
Timeline
came true partly did not not due / being checked / too vague
Calibration score: shown after 10 checked forecasts with a stated likelihood (now 0).
How they speak about the future: based on data 11, stated on authority 1.
Kinds of claim: forecast 11, commitment 1. · Download this report card as a picture
In the nine words
πρόγνωσιςInference from evidence10 · 83%προαναγγελίαPublic pre-announcement1 · 8%μαντείαInspired knowledge1 · 8%
How to read this
Each box is one sentence a public figure or institution said about the future, word for word, with a link to the official text. Can be checked means it names what will happen, by when, and how likely - so it can be compared with official figures later. Too vague to check means it does not. Ambiguity (0-100) is how many different ways the sentence can be read. When the date passes, the forecast is compared with official data and marked came true, partly or did not come true. Labels judge the sentence, never the person. Full guide and glossary.On the record (12)
We successfully delivered on our $4 billion net cost savings target from our ongoing - 1 - cost realignment program, and, as captured in our 2025 financial guidance, we have increased our overall savings target to approximately $4.5 billion by the end of this year.
In addition, we remain on track to deliver $1.5 billion of net cost savings from the first phase of our Manufacturing Optimization Program by the end of 2027, with initial savings expected in the latter part of 2025.
In addition, we are on track to deliver at least $4.0 billion in annual net cost savings by the end of 2024 from our cost realignment program.
We are prepared to execute our commercial strategy to drive continued growth from our newly launched and acquired products, and to deliver on our targeted cost savings that we expect will expand our operating margins in 2024 and beyond.
With expected contributions from our new product launches, this puts us squarely on track to meet our full-year non-COVID operational revenue growth target of 6% to 8%.
Combined with the momentum of our non-COVID product portfolio and U.S. commercialization of Paxlovid, we expect the program to yield improved operating margins this year and help drive Pfizer’s growth through the end of the decade and beyond.
In addition, we launched our cost realignment program, from which we expect to achieve at least $3.5 billion of net cost savings by the end of 2024.
We continue to expect the transaction to close in late 2023 or early 2024, subject to the satisfaction of customary closing conditions.
Our first-quarter results were in line with our expectations, underlining our continued confidence in achieving 7% to 9% operational revenue growth for fiscal-year 2023, excluding our COVID-19 products and anticipated foreign exchange impacts.
Integration planning for our proposed acquisition of Seagen is underway, and we continue to expect the transaction to close in late 2023 or early 2024, subject to the satisfaction of customary closing conditions.
We expect the majority of this growth to occur in the second half of 2023, given the timing of our expected near-term launches.
Looking forward to 2023, we expect strong topline growth of 7% to 9% excluding our COVID-19 products and anticipated foreign exchange impacts.
Also said - not checkable as stated (1 newest)
Remarks about the future with no date, figure or likelihood that could be checked. They are kept on the record and shown here, but not scored.
In addition, we continue to progress our cost realignment program and remain on track to deliver on our targeted cost savings goal by the end of the year.